Company profile: Luxendo
1.1 - Company Overview
Company description
- Provider of proprietary light-sheet fluorescence microscopy instruments based on Single Plane Illumination Microscopy (SPIM). Offers MuVi SPIM, InVi SPIM Lattice Pro, LCS SPIM, and TruLive3D Imager, plus Acquifer HIVE for centralized data storage and computing and LuxBundle Software for acquisition, viewing, and post-processing.
Products and services
- InVi SPIM Lattice Pro: An inverted light-sheet microscope with advanced illumination options, offering various beam shapes for high-resolution 3D imaging of live samples
- MuVi SPIM: A modular light-sheet microscope that supports high-speed volumetric acquisition of dynamic processes in live specimens and cleared sample imaging for diverse imaging needs
- TruLive3D Imager: A light-sheet microscope optimized for fast 3D multi-sample volume imaging of live specimens, suitable for time-lapse and high-throughput imaging of 3D spheroids, organoids, and small embryos
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Luxendo
Avitide
HQ: United States
Website
- Description: Provider of customized affinity purification solutions for biopharmaceuticals, including AVIPure affinity resins for custom and platform use, proprietary solutions to improve bioprocessing and manufacturing, a flexible, scalable commercial resin supply supported by ISO 9001:2015 operations, regulatory support and documentation, and AVIPure-AAV8 for single-step AAV8 purification with high yield, purity, and capacity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avitide company profile →
Ingenium Pharmaceuticals
HQ: Germany
Website
- Description: Provider of drug development, operating as a subsidiary of Probiodrug AG, an integrated drug development company; founded in 1998 as a spin-off from the German Human Genome Project.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ingenium Pharmaceuticals company profile →
Indigo Biosciences
HQ: United States
Website
- Description: Provider of nuclear receptor-focused products and services addressing therapeutic drug targets, including cell-based luciferase reporter assay kits for GPCR and nuclear receptors, Live Cell Multiplex assays to quantify live cells alongside nuclear receptor assays, INDIGlo luciferase detection reagent, environmental testing bioassays, and an ortholog assay portfolio for cross-species receptor activity comparison aiding selection of animal models for drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Indigo Biosciences company profile →
Janvier Labs
HQ: France
Website
- Description: Provider of rodent research models and services, including immunodeficient models for studies in infectious diseases, immune system mechanisms, vaccine development, and cancer immunotherapy; humanized NXG-HIS mice with human-like immune systems for preclinical oncology and immunology; metabolic disease models; aged C57BL/6JRj mice and WISTAR rats; customized genetic model support; and SOPF/SPF colony management and logistics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Janvier Labs company profile →
Peak Proteins
HQ: United Kingdom
Website
- Description: Provider of chemistry services, established by ex-AstraZeneca protein biochemistry and structural biology scientists.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Peak Proteins company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Luxendo
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Luxendo
2.2 - Growth funds investing in similar companies to Luxendo
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Luxendo
4.2 - Public trading comparable groups for Luxendo
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →